Drugs / pentavalent antimony
pentavalent antimony
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01300975 | Jan 2011 → Jul 2012 | cutaneous leishmaniasis | Fundacion Nacional de Dermatologia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentavalent antimony | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01300975 ↗ |
| Known as | Glucantime | “Until recently, the standard treatment for the leishmaniases was pentavalent antimony (Glucantime or Pentostam).” NCT01300975 ↗ |
| Known as | Pentostam | “Until recently, the standard treatment for the leishmaniases was pentavalent antimony (Glucantime or Pentostam).” NCT01300975 ↗ |
| Route | Other | “3 intralesional injections of antimony at D1, D3 and D7” NCT01300975 ↗ |